PMID- 16402954
OWN - NLM
STAT- MEDLINE
DCOM- 20060316
LR  - 20220311
IS  - 1442-6404 (Print)
IS  - 1442-6404 (Linking)
VI  - 33
IP  - 6
DP  - 2005 Dec
TI  - Extensive submacular haemorrhage in polypoidal choroidal vasculopathy managed by 
      sequential gas displacement and photodynamic therapy: a pilot study of one-year 
      follow up.
PG  - 611-8
AB  - BACKGROUND: Polypoidal choroidal vasculopathy (PCV) with peculiar vascular 
      lesions presents frequently as recurrent submacular haemorrhage. The best 
      treatment is still not certain. It is the authors' objective to evaluate the 
      1-year safety and efficacy of photodynamic therapy (PDT) using verteporfin for 
      persistent macular PCV after pneumatic displacement of the massive submacular 
      haemorrhage with intravitreal perfluoropropane (C(3)F(8)). METHODS: A 
      prospective, non-comparative, interventional case series on patients with 
      extensive and thick submacular haemorrhage secondary to PCV, which was displaced 
      pneumatically with intravitreal pure 0.4 ml C(3)F(8). Fluorescein angiography and 
      indocyanine green angiography were repeated 1-2 weeks later to delineate any 
      persistent active leaking polypoidal lesions, which were then treated with PDT. 
      Retreatment might be considered in each follow up at every 3 months. RESULTS: Six 
      eyes of six patients with the mean age of 53.6 years had been recruited and 
      completed 1-year follow up. The mean baseline Snellen equivalent best-corrected 
      visual acuity (BCVA) was 6/92 and the mean final BCVA at 1 year was 6/17. The 
      mean improvement in logMAR BCVA after the sequential treatments was seven lines 
      (range +3 to +19 lines) (Wilcoxon signed-ranks test, P = 0.03). All patients had 
      at least moderate visual gains. No patient suffered serious complications from 
      PDT. CONCLUSIONS: This first report on combined treatment with intravitreal gas 
      injection and sequential PDT on PCV seems to be a well-tolerated option. Further 
      comparative studies with larger sample size and longer follow up are warranted.
FAU - Chan, Wai-Man
AU  - Chan WM
AD  - Department of Ophthalmology and Visual Sciences, The Chinese University of Hong 
      Kong, Prince of Wales Hospital, Shatin, Hong Kong, China. cwm6373@netvigator.com
FAU - Liu, David T L
AU  - Liu DT
FAU - Lai, Timothy Y Y
AU  - Lai TY
FAU - Li, Haitao
AU  - Li H
FAU - Tong, Jian-Ping
AU  - Tong JP
FAU - Lam, Dennis S C
AU  - Lam DS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Clin Exp Ophthalmol
JT  - Clinical & experimental ophthalmology
JID - 100896531
RN  - 0 (Fluorocarbons)
RN  - 0 (Photosensitizing Agents)
RN  - 0 (Porphyrins)
RN  - 0X9PA28K43 (Verteporfin)
RN  - CK0N3WH0SR (perflutren)
RN  - IX6J1063HV (Indocyanine Green)
SB  - IM
MH  - Choroid/*blood supply
MH  - Choroid Diseases/complications/diagnosis/*drug therapy
MH  - Combined Modality Therapy
MH  - Female
MH  - Fluorescein Angiography
MH  - Fluorocarbons/*administration & dosage
MH  - Follow-Up Studies
MH  - Humans
MH  - Indocyanine Green
MH  - Injections
MH  - Male
MH  - Middle Aged
MH  - Peripheral Vascular Diseases/complications/diagnosis/*drug therapy
MH  - *Photochemotherapy
MH  - Photosensitizing Agents/therapeutic use
MH  - Pilot Projects
MH  - Porphyrins/therapeutic use
MH  - Prospective Studies
MH  - Retinal Hemorrhage/diagnosis/*drug therapy/etiology
MH  - Treatment Outcome
MH  - Verteporfin
MH  - Visual Acuity/physiology
EDAT- 2006/01/13 09:00
MHDA- 2006/03/17 09:00
CRDT- 2006/01/13 09:00
PHST- 2006/01/13 09:00 [pubmed]
PHST- 2006/03/17 09:00 [medline]
PHST- 2006/01/13 09:00 [entrez]
AID - CEO1105 [pii]
AID - 10.1111/j.1442-9071.2005.01105.x [doi]
PST - ppublish
SO  - Clin Exp Ophthalmol. 2005 Dec;33(6):611-8. doi: 10.1111/j.1442-9071.2005.01105.x.